Bryn Mawr Capital Management’s Novo Nordisk NVO Stock Holding History

Bryn Mawr Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,002	Closed	-$204K	–	459
2025 Q4	$204K	Buy	+4,002	New	+$205K	0.01%	431
2025 Q3	–	Sell	-3,626	Closed	-$250K	–	450
2025 Q2	$250K	Buy	3,626 +12	+0.3%	+$816	0.01%	366
2025 Q1	$251K	Sell	3,614 -4,798	-57%	-$396K	0.02%	341
2024 Q4	$724K	Sell	8,412 -66	-0.8%	-$7.14K	0.04%	251
2024 Q3	$1.01M	Sell	8,478 -195	-2%	-$26K	0.05%	224
2024 Q2	$1.24M	Sell	8,673 -305	-3%	-$40.4K	0.07%	194
2024 Q1	$1.15M	Sell	8,978 -1,045	-10%	-$124K	0.07%	210
2023 Q4	$1.04M	Buy	10,023 +2,672	+36%	+$264K	0.06%	210
2023 Q3	$669K	Buy	+7,351	New	+$648K	0.04%	249

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Bryn Mawr Capital Management's NVO Position: Q1 2026 in Review

Bryn Mawr Capital Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 4,002 shares — an estimated $204K sold.

Bryn Mawr Capital Management first reported a position in NVO in Q3 2023 and held it in 9 quarters. The position peaked at $1.24M in Q2 2024. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Bryn Mawr Capital Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Bryn Mawr Capital Management sold 4,002 Novo Nordisk shares in Q1 2026, an estimated $204K.
Bryn Mawr Capital Management first reported a position in Novo Nordisk in Q3 2023 and held it in 9 quarters.
Bryn Mawr Capital Management's Novo Nordisk position peaked at $1.24M in Q2 2024.
1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q1 2026, filed 4 May 2026.